EF001 獨立非執行董事勞同聲先生、EDE，Ronald Hao Xi先生及林明儀女士。 EF001 其他信息 其他信息 不適用 發行人董事 於本公佈刊發之日，本公司董事會成員包括二名執行董事李其玲女士及熊融禮先生；二名非執行董事梁康民先生及胡碩先生；三名 第 2 頁 共 2 頁 v 1.1.1 免責聲明 | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 東瑞製葯(控股)有限公司 | | 股份代號 | 02348 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年12月31日止年度的末期股息及暫停辦理股份過戶登記手續 | | 公告日期 | 2026年3月27日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | ...

Financial Performance - Revenue for the year ended December 31, 2025, was RMB 1,230,867 thousand, representing a 16.1% increase from RMB 1,060,309 thousand in 2024[2] - Gross profit for the same period was RMB 612,151 thousand, up 6.0% from RMB 577,628 thousand, with a gross margin of 49.7%, down 4.8 percentage points from 54.5%[2] - Profit before tax decreased significantly by 60.8% to RMB 249,613 thousand from RMB 636,949 thousand in 2024[3] - Net profit for the year was RMB 211,107 thousand, a decline of 62.5% compared to RMB 562,762 thousand in the previous year[3] - Basic earnings per share for the year was RMB 0.14, down 63.2% from RMB 0.38 in 2024[3] - Total revenue for the year ending December 31, 2025, is projected to be RMB 1,230,867,000, with external sales contributing RMB 1,160,655,000[15] - Adjusted profit before tax for the year ending December 31, 2025, is expected to be RMB 249,613,000, reflecting a significant increase from RMB 636,949,000 in the previous year[15] - The company reported a total profit of RMB 426,777,000 for the pharmaceutical segment after adjustments, compared to RMB 364,236,000 in the previous year[15] - The total tax expense for 2025 was RMB 38,506,000, significantly lower than RMB 74,187,000 in 2024, reflecting a decrease of 48.2%[31] - The basic earnings per share attributable to equity holders of the parent for 2025 was RMB 142.5, down from RMB 375.5 in 2024[37] - The net profit attributable to the company's owners for the year was approximately RMB 213,971,000, a decrease of 62.1% compared to RMB 564,940,000 in the previous year[79] Assets and Liabilities - Total assets less current liabilities amounted to RMB 3,515,416 thousand, compared to RMB 3,454,673 thousand in 2024[6] - The company reported a total equity of RMB 3,385,023 thousand, an increase from RMB 3,326,668 thousand in the previous year[6] - Total assets as of December 31, 2025, are reported at RMB 4,009,385,000, with total liabilities at RMB 624,362,000[16] - The company's trade receivables amounted to RMB 145,346,000 in 2025, up from RMB 123,895,000 in 2024, reflecting a growth of 17.3%[38] - The total impairment loss for trade receivables at year-end was RMB 2,166,000, compared to RMB 1,597,000 in 2024, indicating a rise in credit risk[38] - The company's net assets attributable to owners were approximately RMB 3,385,023,000, with a return on equity of 6.3%, down from 17.0% the previous year[80] - The accounts receivable as of December 31, 2025, were approximately RMB 143,180,000, representing a growth of 17.1% compared to RMB 122,298,000 as of December 31, 2024[84] Dividends - The company maintained a dividend policy with a proposed total annual dividend of HKD 0.063, down 33.7% from HKD 0.095 in 2024[2] - The proposed final dividend for 2025 is HKD 0.048 per share, totaling approximately HKD 72,171,000, which is a slight increase from HKD 72,091,000 in 2024[45] - The total dividend for 2025 will be HKD 0.063 per share, a decrease of approximately 33.7% compared to the total dividend of HKD 0.063 per share and special dividend of HKD 0.032 per share in 2024, but the payout ratio will increase to 39.3% from 23.5% in 2024, an increase of 15.8 percentage points[45] Research and Development - Research and development costs increased to RMB 83,479 thousand from RMB 70,831 thousand, indicating ongoing investment in innovation[3] - Research and development expenses for 2025 amounted to RMB 83,399,000, an increase of 17.9% from RMB 70,755,000 in 2024[29] - The group is focusing on R&D with 35 products undergoing quality and efficacy consistency studies, with 32 specifications approved as of December 31, 2025[67] - The group plans to continue increasing R&D investment to enrich its product pipeline and ensure new products are launched annually, focusing on therapeutic areas such as cardiovascular, anti-infective, and endocrine diseases[66] Sales Performance - Revenue from pharmaceutical product sales was RMB 1,215,157 thousand in 2025, up from RMB 1,058,297 thousand in 2024, indicating a growth of 14.84%[21] - The sales volume and revenue of the "Xikewai" (Cetirizine Hydrochloride Tablets), "Shumaitong" (Atorvastatin Calcium Tablets), and "Ruifuen" (Entecavir Dispersible Tablets) have both increased, despite a slight decline in sales for the "An" series products[47] - The sales volume of powder injections increased by 67.3% and sales revenue increased by 73.0% compared to the same period in 2024, driven by successful bids in national and local procurement[49] - The sales of intermediates and raw materials reached RMB 70,212,000, a significant increase of 67.0% year-over-year, while finished drug sales were RMB 1,160,655,000, growing by 14%[75] - Sales of the antihypertensive product series decreased by 5.2%, totaling RMB 316,901,000, which accounts for 25.7% of the company's total sales[60] - The sales of the antihyperlipidemic product series increased by 13.0%, reaching RMB 338,407,000, representing 27.5% of total sales[61] - The antiviral product line, particularly entecavir dispersible tablets, achieved sales of RMB 165,422,000, a 17.1% increase from the previous year, accounting for 13.4% of total sales[62] - The antibiotic series, particularly the injection of cefoperazone sodium and sulbactam sodium, saw a sales increase of 73.0%, totaling RMB 188,319,000, which is 15.3% of total sales[63] Operational Efficiency - Total expenses for the year ended December 31, 2025, were RMB 93,817 thousand, an increase from RMB 56,298 thousand in 2024[27] - The total expenses for the year were approximately RMB 422,066,000, which is an increase of RMB 33,126,000 from the previous year, accounting for 34.3% of total sales[76] - The operating profit from the finished drug segment was approximately RMB 496,311,000, an increase of RMB 71,100,000 from the previous year, while the intermediates and raw materials segment reported a loss of RMB 69,534,000[77] - The total employee benefits expenses for 2025 were RMB 222,623,000, a decrease of 3.5% from RMB 230,667,000 in 2024[29] Strategic Initiatives - The company plans to increase R&D investment and strengthen its competitive edge in the procurement market, focusing on high-value varieties and exploring innovative drug collaborations[50] - The company is enhancing its production capabilities at its Suzhou and Lanzhou facilities to meet the latest regulatory standards and improve product quality while reducing production costs[53] - The company aims to align its development strategy with national policies supporting innovative drug research and development, focusing on small molecules and innovative drugs through collaboration and acquisitions[52] - The company focuses on six core strategies, including R&D innovation, production capacity optimization, and market expansion to address industry challenges and seize development opportunities[54] - The group is actively expanding its customer base and enhancing its market share in intermediates and raw materials through CDMO business development[64] Compliance and Governance - The company has adopted the International Accounting Standard 21 (Revised) regarding currency convertibility, which has no impact on the financial statements due to the use of convertible currencies[11] - The company has not adopted any other new accounting standards or amendments that are not yet effective[11] - The group is committed to quality management and compliance, with ongoing improvements in safety and environmental protection measures[68]

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED 東瑞製葯（控股）有限公司* （於開曼群島註冊成立的有限公司） 董事會召開日期 東瑞製葯（控股）有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司董 事會會議將於二零二六年三月二十七日（星期五）舉行，藉以(其中包括)批准刊發本公 司及其附屬公司截至二零二五年十二月三十一日止年度的全年業績公告，以及考慮建議 派發末期股息(如有)。 承董事會命 東瑞製葯（控股）有限公司 公司秘書 彭潔玲 香港，二零二六年三月十三日 * 以供識別之用 （股份代號：2348） 於本公告刊發之日，本公司董事會包括兩名執行董事李其玲女士及熊融禮先生；兩名非執行董 事梁康民先生及胡碩先生；以及三名獨立非執行董事勞同聲先生,EDE, Ronald Hao Xi先生及林 明儀女士。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 東瑞製葯(控股)有限公司 呈交日期: 2026年3月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02348 | 說明 | 東瑞製葯(控股)有限公司 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | HKD | | 0.05 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 20,000,000,000 | HKD | | 0.05 | HKD | | 1,0 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 東瑞製葯(控股)有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02348 | 說明 | 東瑞製葯(控股)有限公司 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 HKD | | | 0.05 HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 20,000,000,000 HKD | | | 0.05 HKD | | 1,000,000,000 | 本月底法定 ...

本月底法定/註冊股本總額： HKD 1,000,000,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 東瑞製葯(控股)有限公司 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02348 | 說明 | | 東瑞製葯(控股)有限公司 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | HKD | | 0.05 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 20,000,000 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 東瑞製葯(控股)有限公司 呈交日期: 2025年12月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02348 | 說明 | 東瑞製葯(控股)有限公司 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | HKD | | 0.05 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 20,000,000,000 | HKD | | 0.05 | HKD | | 1 ...

Core Viewpoint - The chairman of the Hong Kong Stock Exchange, Li Qiling, has increased his stake in Dongrui Pharmaceutical (02348) by purchasing 52,000 shares at a price of HKD 1.22 per share, totaling approximately HKD 63,400 [1] Summary by Category Shareholding Activity - After the purchase, the total number of shares held by Li Qiling is approximately 711 million, representing a holding percentage of 47.26% [1] Related Parties - The transaction involves other related parties, specifically Xiong Rongli [1]

Group 1 - The chairman of Dongrui Pharmaceutical (02348), Li Qiling, increased his shareholding by 52,000 shares at a price of HKD 1.22 per share, totaling approximately HKD 63,400 [1] - After the purchase, the total number of shares held by Li Qiling is approximately 711 million, representing a holding percentage of 47.26% [1] Group 2 - The transaction involves other related parties, specifically Xiong Rongli [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 東瑞製葯(控股)有限公司 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02348 | 說明 | 東瑞製葯(控股)有限公司 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 HKD | | | 0.05 HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 20,000,000,000 HKD | | | 0.05 HKD | | 1,000,000,000 | 本月底 ...